Early prediction of IgA nephropathy progression: Proteinuria and AOPP are strong prognostic markers

Kidney International

Volumn 66, Issue 4, 2004, Pages 1606-1612

  Descamps Latscha, Béatrice ^a   Witko Sarsat, Véronique ^b   Nguyen Khoa, Thao ^b   Nguyen, Anh Thu ^b   Gausson, Valérie ^b   Mothu, Nadya ^b   Cardoso, Camila ^b   Noël, Laure Hélène ^b   Guérin, Alain P ^b   London, Gérard M ^b   Jungers, Paul ^b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b NONE

Author keywords

Advanced oxidation protein products; IgA nephropathy; Inflammation; Oxidative stress; Renal disease progression

Indexed keywords

ADVANCED OXIDATION PROTEIN PRODUCT; ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE COURSE; FEMALE; HEMODIALYSIS; HISTOPATHOLOGY; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; INFLAMMATION; KIDNEY BIOPSY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OXIDATIVE STRESS; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEINURIA; REGRESSION ANALYSIS;

EID: 4644310399     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.00926.x     Document Type: Article

References (35)

1. DONADIO JV, GRANDE JP: IgA nephropathy. N Engl J Med 347:738-748, 2002
2. ALAMARTINE E, SABATIER X, GUERIN C, et al: Prognostic factors in mesangial IgA glomerulonephritis: An extensive study with univariate and multivariate analyses. Am J Kidney Dis 18:12-19, 1991
3. KOYAMA A, IGARASHI M, KOBAYASHI M: Natural history and risk factors for immunoglobulin A nephropathy in Japan. Research Group on Progressive Renal Diseases. Am J Kidney Dis 29:526-532, 1997
4. RADFORD MG, JR., DONADIO JV, JR., BERGSTRALH EJ, GRANDE JP: Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol 8:199-207, 1997
5. D'AMICO G: Natural history of idiopathic IgA nephropathy: Role of clinical and histological prognostic factors. Am J Kidney Dis 36:227-237, 2000
6. FLOEGE J, FEEHALLY J: IgA nephropathy: Recent developments. J Am Soc Nephrol 11:2395-2403, 2000
7. BARTOSIK LP, LAJOIE G, SUGAR L, CATTRAN DC: Predicting progression in IgA nephropathy. Am J Kidney Dis 38:728-735, 2001
8. FRIMAT L, BRIANCON S, HESTIN D, et al: IgA nephropathy: Prognostic classification of end-stage renal failure. Nephrol Dial Transplant 12:2569-2575, 1997
9. POZZI C, BOLASCO PG, FOGAZZI GB, et al: Corticosteroids in IgA nephropathy: A randomised controlled trial. Lancet 353:883-887, 1999
10. KATAFUCHI R, IKEDA K, MIZUMASA T, et al: Controlled, prospective trial of steroid treatment in IgA nephropathy: A limitation of low-dose prednisolone therapy. Am J Kidney Dis 41:972-983, 2003
11. GRANDE JP, WALKER HJ, HOLUB BJ, et al: Suppressive effects of fish oil on mesangial cell proliferation in vitro and in vivo. Kidney Int 57:1027-1040, 2000
12. WITKO-SARSAT V, FRIEDLANDER M, CAPEILLERE-BLANDIN C, et al: Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 49:1304-1313, 1996
13. WITKO-SARSAT V, FRIEDLANDER M, NGUYEN-KHOA T, et al: Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 161:2524-2532, 1998
14. COCKROFT DW, GAULT MH: Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41, 1976
15. NGUYEN-KHOA T, MASSY ZA, DE BANDT JP, et al: Oxidative stress and haemodialysis: Role of inflammation and duration of dialysis treatment. Nephrol Dial Transplant 16:335-340, 2001
16. DONADIO JV, JR., GRANDE JP, BERGSTRALH EJ, et al: The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Mayo Nephrology Collaborative Group. J Am Soc Nephrol 10:1772-1777, 1999
17. BOGENSCHUTZ O, BOHLE A, BATZ C, et al: IgA nephritis: On the importance of morphological and clinical parameters in the long-term prognosis of 239 patients. Am J Nephrol 10:137-147, 1990
18. KATAFUCHI R, OH Y, HORI K, et al: An important role of glomerular segmental lesions on progression of IgA nephropathy: A multivariate analysis. Clin Nephrol 41:191-198, 1994
19. HAAS M: Histologic subclassification of IgA nephropathy: A clinicopathologic study of 244 cases. Am J Kidney Dis 29:829-842, 1997
20. VLEMING LJ, DE FIJTER JW, WESTENDORP RG, et al: Histomorphometric correlates of renal failure in IgA nephropathy. Clin Nephrol 49:337-344, 1998
21. TO KF, CHOI PC, SZETO CC, et al: Outcome of IgA nephropathy in adults graded by chronic histological lesions. Am J Kidney Dis 35:392-400, 2000
22. BEUKHOF JR, KARDAUN O, SCHAAFSMA W, et al: Toward individual prognosis of IgA nephropathy. Kidney Int 29:549-556, 1986
23. LAI FM, SZETO CC, CHOI PC, et al: Characterization of early IgA nephropathy. Am J Kidney Dis 36:703-708, 2000
24. DANIEL L, SAINGRA Y, GIORGI R, et al: Tubular lesions determine prognosis of IgA nephropathy. Am J Kidney Dis 35:13-20, 2000
25. DONADIO JV, BERGSTRALH EJ, GRANDE JP, RADEMCHER DM: Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathy. Nephrol Dial Transplant 17:1197-1203, 2002
26. FOFI C, PECCI G, GALLIANI M, et al: IgA nephropathy: Multivariate statistical analysis aimed at predicting outcome. J Nephrol 14:280-285, 2001
27. RUGGENENTI P, PERNA A, GHERARDI G, et al: Chronic proteinuric nephropathies: Outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am J Kidney Dis 35:1155-1165, 2000
28. MASCHIO G, CAGNOLI L, CLARONI F, et al: ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy: A multicentre, randomized, placebo-controlled study. Nephrol Dial Transplant 9:265-269, 1994
29. CATTRAN DC, GREENWOOD C, RITCHIE S: Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin a nephropathy: A comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. Am J Kidney Dis 23:247-254, 1994
30. RUGGENENTI P, PERNA A, BENINI R, et al: In chronic nephropathies prolonged ACE inhibition can induce remission: Dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. J Am Soc Nephrol 10:997-1006, 1999
31. RUGGENENTI P, PERNA A, GHERARDI G, et al: Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 354:359-364, 1999
32. KUEMMERLE NB, KRIEG RJ, JR., CHAN W, et al: Influence of alpha-tocopherol over the time course of experimental IgA nephropathy. Pediatr Nephrol 13:108-112, 1999
33. DONADIO JV, JR., LARSON TS, BERGSTRALH EJ, GRANDE JP: A randomized trial of high-dose compared with low-dose omega-3 fatty acids in severe IgA nephropathy. J Am Soc Nephrol 12:791-799, 2001
34. LOCATELLI F, POZZI C, DEL VECCHIO L, et al: Combined treatment with steroids and azathioprine in IgA nephropathy: Design of a prospective randomised multicentre trial. J Nephrol 12:308-311, 1999
35. TEPEL M, VAN DER GIET M, STATZ M, et al: The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: A randomized, controlled trial. Circulation 107:992-995, 2003